Emcure Pharmaceuticals Ltd: History, Latest Updates, Milestones, Subsidiaries and Share Price

Emcure Pharmaceuticals Ltd: History, Latest Updates, Milestones, Subsidiaries and Share Price

Emcure Pharmaceuticals Ltd: History, Latest Updates, Milestones, Subsidiaries and Share Price

 

INTRODUCTION 

Emcure Pharmaceuticals Ltd. is an Indian pharmaceutical company engaged in the development, manufacturing and marketing of healthcare products across domestic and international markets. Established in 1981, the company has built a presence in more than 70 countries, with a portfolio of over 350 brands covering major therapeutic areas and diverse patient needs.

 

The Emcure share price is one of the market indicators used to track the company's listed performance and developments. Emcure's operations are supported by 5 R&D centres and 13 advanced manufacturing facilities across India, with capabilities spanning pharmaceuticals and specialised healthcare products. The company has also expanded its business through subsidiaries and strategic initiatives across different therapeutic segments. Market participants can track the Emcure share price and other market information through a share market app best suited to their requirements.

 

Emcure Pharmaceuticals Ltd Moves in 2026

  • Poviztra approved for MASH indication: In July 2026, Emcure expanded the use of Poviztra for Metabolic Dysfunction-Associated Steatohepatitis (MASH) after receiving approval from the Central Drugs Standard Control Organisation (CDSCO). The development added another therapeutic application for the semaglutide-based product.

  • Gennova stake acquisition: In July 2026, Emcure Pharmaceuticals acquired the remaining 12.05% stake in Gennova Biopharmaceuticals, taking its ownership of the biotechnology company to 100%. The transaction further consolidated Gennova within the Emcure group.

  • Mantra Pharma expansion: In July 2026, Emcure's subsidiary Marcan Pharmaceuticals entered into an agreement to acquire the remaining Class E Special Shares of Canada's Mantra Pharma for C$50 million. The transaction is part of the group's international business expansion.

  • Q1 FY27 performance: For the quarter ended June 30, 2026, Emcure reported consolidated revenue of Rs. 2,580 crore, up 22.8% year-on-year, while consolidated PAT increased 36.2% to Rs. 292 crore. These financial developments provide context for tracking the Emcure share price alongside the company's operating performance.

  • Final dividend approved: In September 2026, Emcure approved a final dividend of Rs. 3.60 per equity share for FY26. The dividend was approved at the company's Annual General Meeting.

 

Evolution of Emcure Pharmaceuticals Ltd: From Past to Present 

Emcure Pharmaceuticals Ltd. has evolved over more than four decades, beginning in 1981 with a focus on providing quality and affordable healthcare solutions. The company gradually expanded its capabilities from pharmaceutical manufacturing into APIs, biologics, specialised formulations and advanced drug delivery systems. In 1994, Emcure established its first API manufacturing unit, followed by the introduction of its first biologic product in 2002 and expansion into international markets in 2006. Over the years, the company strengthened its research and development capabilities, developed expertise in areas such as chiral chemistry and biopharmaceuticals, and expanded its presence to more than 70 countries. In 2024, Emcure was listed on the NSE and BSE and launched Emcutix as a wholly owned dermatology subsidiary. In 2025, Zuventus became a wholly owned subsidiary, while the Emcure Research Centre was inaugurated in Ahmedabad. These developments reflect the company's transition from its early pharmaceutical operations to its present-day focus on research, specialised healthcare products and global markets.

 

Name

Emcure Pharmaceuticals Limited

Founded year

1981

Headquarters

Mumbai, India

Sector

Pharmaceuticals

Current chairman

Satish Mehta

Market Cap

Rs. 37,220.28 Cr.

Geographical presence

Global

Nse code

Emcure

Bse code

544210

 

Timeline of Emcure Pharmaceuticals Ltd

 

Year

Fact

Description

1981

The Beginning

Emcure was founded to provide quality and affordable healthcare.

1994

API Manufacturing

Established its first API manufacturing unit.

2002

Biologics

Introduced its first biologic product.

2006

Global Expansion

Expanded into overseas markets and 70+ countries.

2010

Chiral Chemistry

Developed and marketed 11 chiral molecules.

2015

Biologics Leadership

Became a domestic leader in three biologic therapies.

2018

Formulations

Received recognition for Emluz and Orofer XT.

2021

Research

Reported 234 global patent filings, with 201 approved.

2023

Biopharmaceuticals

Expanded its research capabilities across mRNA technology, vaccines and complex APIs.

2024

IPO & Emcutix

Listed on NSE/BSE and launched Emcutix as a wholly owned subsidiary.

2025

Expansion

Zuventus became wholly owned and ERC was inaugurated in Ahmedabad.

 

Inside Emcure Pharmaceuticals Ltd: Exploring Subsidiary Ventures

Corporate action: As of 25 September 2026, the Emcure share price was Rs. 1,950.60 at the market close. Emcure Pharmaceuticals has paid an equity dividend of Rs. 3.60 per share over the past 12 months. The company’s final dividend of Rs. 3.60 per share for FY26 had an ex-date and record date of 4 September 2026. At the stated market price, the company’s dividend yield was approximately 0.18%.

 

Main News:

  • August 2026: Emcure reported its Q1 FY27 financial results, with consolidated revenue rising 22.8% year-on-year to Rs. 2,580 crore and consolidated PAT increasing 36.2% to Rs. 292 crore.

  • July 2026: Emcure acquired the remaining 12.05% stake in Gennova Biopharmaceuticals, taking its ownership of the company to 100%.

  • July 2026: Emcure expanded the use of Poviztra for MASH following CDSCO approval for semaglutide in the indication. The development was also reflected in market activity around the Emcure share price.

  • July 2026: Emcure's subsidiary Marcan Pharmaceuticals agreed to acquire the remaining Class E Special Shares of Canada's Mantra Pharma for C$50 million, supporting the group's expansion in the international pharmaceutical market.

 

Emcure Pharmaceuticals Ltd Share Price NSE/BSE:

 

Company name

Sector

Share price

Emcure Pharmaceuticals Ltd

Pharmaceuticals & Drugs

Emcure share price

The Emcure share price changes with market conditions and trading activity. Investors can track the latest Emcure pharma share price NSE and Emcure share price BSE through exchange data. Those looking to participate in the market can open trading account with a registered intermediary.

 

Financial Snapshot & Investor Analysis

Emcure Pharmaceuticals Ltd. had a market capitalization of Rs. 37,220.28 Cr. and an enterprise value of Rs. 38,569.68 Cr. The company’s P/E stood at 45.94, while its P/B ratio was 9.55, with a book value of Rs. 205.51 per share. As reported, Emcure had Rs. 1,366.27 Cr. in debt and Rs. 16.88 Cr. in cash.

 

From an operating perspective, sales growth was 19.65%, while profit growth stood at 131.12%. The company recorded an ROE of 21.84% and ROCE of 24.27%, with promoters holding 77.83% of the equity. Its dividend yield was 0.18%, providing additional context when reviewing the company’s financial profile.

 

Industry Comparison: How Emcure Pharmaceuticals Ltd Stacks Up Against Peers

To put Emcure Pharmaceuticals Ltd.’s financial metrics in context, the table compares the company with selected pharmaceutical peers on valuation, earnings and return ratios. The comparison includes metrics such as P/E, P/B, EPS, ROE, ROCE and EV/EBITDA.

 

Company

Price (Rs.)

M.Cap (Cr.)

P/B

P/E

EPS (Rs.)

ROE (%)

ROCE (%)

P/S

EV/EBITDA

Ipca Laboratories

1,969.50

50,000.03

5.99

40.20

49.02

15.23

19.75

6.86

24.23

Anthem Biosciences

875.00

49,229.81

15.13

78.86

11.08

23.99

31.30

23.56

50.64

Gland Pharma

2,910.00

48,136.97

4.33

34.51

84.52

12.67

17.18

10.57

21.59

GlaxoSmithKline Pharma

2,814.05

47,699.66

19.00

44.98

62.60

47.94

65.81

12.58

30.76

Ajanta Pharma

3,547.10

44,332.96

9.77

44.01

80.61

24.15

31.43

9.15

29.47

Emcure Pharmaceuticals

1,961.95

37,004.96

9.49

45.67

42.71

21.84

24.27

7.06

26.35



The figures show that Emcure’s ROE stood at 21.84% and ROCE at 24.27%, while its P/E was 45.67 and EV/EBITDA was 26.35. These indicators provide a broader view of the company’s valuation and financial performance alongside its pharmaceutical peers.

 

Achievements & Milestone

Emcure Pharmaceuticals Ltd. has earned recognition across pharmaceutical research, patient-focused initiatives, workplace safety and organisational development. These milestones also provide context for tracking the Emcure share price alongside the company’s business developments.

Year

Achievement

2021–2024

Received the IDMA Best Formulation Patent Award for its Carmustine Patents Portfolio.

2024

Won a Bronze Award at the IHW Patients First Awards for its SAKHI women's health initiative.

2024–2025

Received a Silver Award at the CII HR Ideathon for the STAR – API Health Transformation Initiative.

Up to 2022

Earned multiple National Safety Council recognitions for its Hinjawadi facility.

2016–2019

Received IDMA recognitions for API and Indian patent categories.

Recent years

Earned Impact Awards, including Platinum and Silver honours, for brand and platform initiatives.



Conclusion 

Emcure Pharmaceuticals Ltd. has developed from a pharmaceutical company established in 1981 into a global healthcare business with operations across more than 70 countries. Its 2026 developments, including the Gennova stake acquisition, Poviztra expansion, Mantra Pharma transaction and Q1 FY27 performance, highlight the company’s ongoing business activities. The Emcure share price and financial metrics provide additional information for tracking its listed performance. Investors can review the company’s business updates, financial results and market data before making decisions through registered stock broker companies.

 

Frequently Asked Questions

Where can I find real-time updates on the Emcure share price ?

Check the latest Emcure share price  and live stock updates on Enrich Money’s stock here.

 

What have been the highest and lowest Emcure share price in the past 52 weeks?

The Emcure share price recorded a 52-week high of Rs. 2,100.70 and The 52-week low of the Emcure share price stands at approximately Rs. 1,260.00 .

 

How do the P/E and P/B ratios of Emcure Pharma compare?

Emcure Pharma has a P/E ratio of 45.70 and a P/B ratio of 9.50. These measures help understand the valuation of the share price of Emcure Pharmaceuticals in relation to its earnings and book value.

 

Does Emcure Pharma pay dividends?

Yes. Emcure Pharma has declared dividends, with its current dividend yield at approximately 0.18%.

 

How much are Emcure Pharma’s shares valued at in terms of face value and book value?

Emcure Pharma’s shares have a face value of Rs. 10, while the book value per share is approximately Rs. 205.51. Face value represents the nominal value assigned to a share, whereas book value indicates its accounting value.

 

What is the debt of Emcure Pharma?

Emcure Pharma reported total debt of Rs. 1,366.27 Cr. This figure forms part of the financial information that can be considered when reviewing the company’s overall financial position and the Emcure pharmaceuticals limited share price.

 

Disclaimer:This blog is dedicated exclusively for educational purposes. Please note that the securities and investments mentioned here are provided for informative purposes only and should not be construed as recommendations.Kindly ensure thorough research prior to making any investment decisions. Participation in the securities market carries inherent risks, and it's important to carefully review all associated documents before committing to investments. Please be aware that the attainment of investment objectives is not guaranteed. It's important to note that the past performance of securities and instruments does not reliably predict future performance.

 

Check our ORCA app to analyze stocks' performance:

Emcure Pharmaceuticals Ltd Share Price

Emcure Pharmaceuticals Ltd Technical Analysis

Emcure Pharmaceuticals Ltd Future share price

Emcure Pharmaceuticals Ltd financials

Emcure Pharmaceuticals Ltd shareholding pattern

Emcure Pharmaceuticals Ltd share news

Emcure Pharmaceuticals Ltd Overview

 

Related Stocks

Ipca Laboratories

Anthem Biosciences

Gland Pharma

Glaxosmithkline Phar

Ajanta Pharma









Related Posts

  • Emcure Pharmaceuticals Ltd: History, Latest Updates, Milestones, Subsidiaries and Share Price

  • One Mobikwik Systems Ltd: History, Latest Updates, Milestones, Business, and Share Price

  • Top 5 Auto Ancillary Stocks India 2026: Price, Growth & Key Metrics